l -Dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction
- 13 July 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 63 (1) , 153-155
- https://doi.org/10.1212/01.wnl.0000131910.72829.9d
Abstract
The authors studied the long-term evolution of levodopa-induced dyskinesia (LID) after levodopa challenge in two groups of six STN-deep brain stimulation-treated Parkinson disease (PD) patients, one requiring medication after surgery and the other not. A dramatic (96%) reduction of LID severity was obtained in the six postoperatively untreated patients compared to a moderate improvement (47%) in the treated group (p < 0.03). These data support dopaminergic stimulation and striatal desensitization as major determinants of LID in PD.Keywords
This publication has 9 references indexed in Scilit:
- Growth Hormone Deficiency: Strategies and Indications to Continue Growth Hormone Therapy in Transition from Adolescence to Adult LifeHormone Research in Paediatrics, 2003
- How do parkinsonian signs return after discontinuation of subthalamic DBS?Neurology, 2003
- Subthalamic DBS replaces levodopa in Parkinson’s diseaseNeurology, 2002
- Levodopa‐induced dyskinesias in Parkinson's disease: Is sensitization reversible?Annals of Neurology, 2000
- De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmosetMovement Disorders, 1998
- Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian PatientsCanadian Journal of Neurological Sciences, 1996
- Fetal nigral transplantation as a therapy for Parkinson's diseaseTrends in Neurosciences, 1996
- Nigrostriatal Damage is Required for Induction of Dyskinesias by l-DOPA in Squirrel MonkeysClinical Neuropharmacology, 1990
- Parkinson's Disease: Follow‐up After “Drug Holiday”The Journal of Clinical Pharmacology, 1986